mmp9 levels  (Proteintech)

Journal: Journal of translational medicine

Article Title: Screening of immune-related secretory proteins linking chronic kidney disease with calcific aortic valve disease based on comprehensive bioinformatics analysis and machine learning.

doi: 10.1186/s12967-023-04171-x

Figure Lengend Snippet: Fig. 8 Development of the diagnostic nomogram model and efficacy assessment. A The nomogram was constructed based on the diagnostic biomarkers. B–D The ROC curve for the diagnostic performance of each candidate biomarker including SLPI (B), and MMP9 (C) and the nomogram model (D) constructed for CKD-related CAVD. E The calibration curve of nomogram model prediction in CKD-related CAVD. The dash line is marked as “Ideal”, which represents the standard curve, and is on behalf of the perfect prediction of the ideal model. The dotted line is marked as “Apparent”, which indicates the uncalibrated prediction curve, while the solid line is marked as “Bias-corrected” and represents the calibrated prediction curve. F DCA for the nomogram model. The black line is marked as “None”, which stands for the net benefit of the assumption that no patients have CAVD. The grey line is marked as “All”, which indicates the net benefit of the assumption that all patients have CAVD, and the purple line is marked as “Nomogram”, and represents the net benefit of the assumption that CKD-related CAVD are identified according to the diagnostic value of CAVD predicted by the nomogram model. G The ROC curve for the diagnostic performance of our nomogram model in predicting patients with sclerotic aortic valve from the GEO database. ROC receiver operating characteristic, DCA decision curve analysis, CAVD calcific aortic valve disease

Article Snippet: In addition, the serum SLPI and MMP9 levels were determined with the indicated ELISA kits (Cusabio, Wuhan, China) in line with the manufacturer’s protocols.

Techniques: Diagnostic Assay, Construct, Biomarker Discovery

Journal: Experimental and Therapeutic Medicine

Article Title: Remifentanil modulates the TLR4‑mediated MMP‑9/TIMP1 balance and NF‑κB/STAT3 signaling in LPS‑induced A549 cells

doi: 10.3892/etm.2022.11778

Figure Lengend Snippet: Antibodies used for western blot analysis.

Article Snippet: ELISA kits were used to measure the levels of inflammatory factors, including IL-6 (cat. no. ZN2272), IL-1β (cat. no. ZN2236) and TNF-α (cat. no. ZN2460; Beijing Biolab Technology Co., Ltd.), as well as the secretion levels MMP9 (cat. no. BMS2016-2; Invitrogen; Thermo Fisher Scientific, Inc.) and TIMP1 (cat. no. PT888; Beyotime Institute of Biotechnology).

Techniques: Western Blot

Journal: Experimental and Therapeutic Medicine

Article Title: Remifentanil modulates the TLR4‑mediated MMP‑9/TIMP1 balance and NF‑κB/STAT3 signaling in LPS‑induced A549 cells

doi: 10.3892/etm.2022.11778

Figure Lengend Snippet: Remifentanil restores TLR4-mediated MMP-9/TIMP1 balance in LPS-treated cells. (A) The expression levels of TLR4, MMP-9 and TIMP1 were measured using western blotting. (B) The ratio of the expression levels of MMP-9 and TIMP1. (C) TIMP1 and MMP-9 secretion levels in the cell supernatant were determined using ELISA. (D) The ratio of the secretion levels of MMP-9 and TIMP1. *** P<0.001 vs. control; # P<0.05, ## P<0.01 and ### P<0.001 vs. LPS. LPS, lipopolysaccharide; TIMP1, tissue inhibitor of metalloproteinase 1; TLR4, Toll-like receptor 4.

Article Snippet: ELISA kits were used to measure the levels of inflammatory factors, including IL-6 (cat. no. ZN2272), IL-1β (cat. no. ZN2236) and TNF-α (cat. no. ZN2460; Beijing Biolab Technology Co., Ltd.), as well as the secretion levels MMP9 (cat. no. BMS2016-2; Invitrogen; Thermo Fisher Scientific, Inc.) and TIMP1 (cat. no. PT888; Beyotime Institute of Biotechnology).

Techniques: Expressing, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Aging Neuroscience

Article Title: Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease

doi: 10.3389/fnagi.2022.889257

Figure Lengend Snippet: Clinical characteristics and serum MMP3 and MMP9 levels of participants in individual groups in the current study.

Article Snippet: Serum MMP9 levels were measured using an ELISA kit (DMP900; R&D Systems, Minneapolis, MN, United States).

Techniques:

Journal: Frontiers in Aging Neuroscience

Article Title: Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease

doi: 10.3389/fnagi.2022.889257

Figure Lengend Snippet: Serum MMP3 and MMP9 levels in PD patients and contr subjects. (A) MMP3 levels in the PD group with early-stage disease were highly decreased in the serum compared with the controls; There was no statistically significant difference in serum MMP3 levels in patients with advanced-stage PD compared to healthy controls; Compared to PD patients with early-stage disease, MMP3 levels in advanced-stage PD patients were higher, while there were no significant differences. (B) MMP9 in the PD group with early-stage disease was increased in the serum compared with the controls; Serum levels were elevated in the advanced-stage PD group relative to the control group; Compared to PD patients with early-stage disease, MMP9 levels in advanced-stage PD patients were higher. PD, Parkinson’s disease; MMP3, Matrix Metalloproteinase 3; MMP9, Matrix Metalloproteinase 9. The central line in each box indicates the median, box edges mark the first and third quartiles, and limits of the vertical lines show ranges. NS, no significance; * P < 0.05.

Article Snippet: Serum MMP9 levels were measured using an ELISA kit (DMP900; R&D Systems, Minneapolis, MN, United States).

Techniques: Control

Journal: Frontiers in Aging Neuroscience

Article Title: Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease

doi: 10.3389/fnagi.2022.889257

Figure Lengend Snippet: ROC curve for serum MMP3 and MMP9 levels comparing the PD group and healthy control group. ROC curve, receiver operating characteristic curve; AUC, area under the curve; CI, confidence interval.

Article Snippet: Serum MMP9 levels were measured using an ELISA kit (DMP900; R&D Systems, Minneapolis, MN, United States).

Techniques: Control

Journal: Frontiers in Aging Neuroscience

Article Title: Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease

doi: 10.3389/fnagi.2022.889257

Figure Lengend Snippet: Correlation of serum matrix metalloproteinase 3 (MMP3) and matrix metalloproteinase 9 (MMP9) levels with disease duration and disease severity in PD patients. (A) Serum MMP3 levels were positively correlated with disease duration (Spearman’s correlation coefficient r = 0.297, P = 0.011, and n = 73). (B) Serum MMP3 levels were positively correlated with UPDRS part III scores (Spearman’s correlation coefficient r = 0.389, P = 0.001, and n = 73). (C) Serum MMP9 levels were positively correlated with UPDRS part III scores (Spearman’s correlation coefficient r = 0.279, P = 0.017, and n = 73). * P < 0.05. (D) Serum MMP9 level was not correlated with the course of disease ( r = 0.063, P = 0.594, and n = 73).

Article Snippet: Serum MMP9 levels were measured using an ELISA kit (DMP900; R&D Systems, Minneapolis, MN, United States).

Techniques:

Journal: Frontiers in Aging Neuroscience

Article Title: Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease

doi: 10.3389/fnagi.2022.889257

Figure Lengend Snippet: Correlation analysis of non-motor symptoms and serum MMP3 and MMP9 levels in PD patients.

Article Snippet: Serum MMP9 levels were measured using an ELISA kit (DMP900; R&D Systems, Minneapolis, MN, United States).

Techniques:

Journal: Frontiers in Aging Neuroscience

Article Title: Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease

doi: 10.3389/fnagi.2022.889257

Figure Lengend Snippet: Correlation of serum Matrix Metalloproteinase 3 (MMP3) with the PDSS score and matrix metalloproteinase 9 (MMP9) levels with the MMSE score in PD patients. (A) Serum MMP3 levels were negatively correlated with the PDSS score (Spearman’s correlation coefficient r = –0.246, P = 0.036, and n = 73). * P < 0.05. (B) Serum MMP9 levels were negatively correlated with the MMSE scores (Spearman’s correlation coefficient r = –0.165, P = 0.162, and n = 73) but were not statistically significant.

Article Snippet: Serum MMP9 levels were measured using an ELISA kit (DMP900; R&D Systems, Minneapolis, MN, United States).

Techniques: